Compass Therapeutics (CMPX) Price & Analysis

Compare

360 Followers

CMPX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.87 - $4.08

Previous CloseN/A

Volume16.21M

Average Volume (3M)794.91K

Market Cap

$438.36M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta2.25

Next Earnings

Jul 30, 2025

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding138,282,500

10 Day Avg. Volume726,826

30 Day Avg. Volume794,910

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$13.20

Price Target Upside332.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe trial achieved statistical significance in the primary endpoint of overall response rate, showing better results for tovecimig + paclitaxel compared to paclitaxel alone.

Financial PositionCompass Therapeutics ended the quarter financially strong with $113 million, expected to provide runway into 2027.

Pipeline DevelopmentThe remainder of the pipeline is on track, with plans to report initial Phase 1 data for CTX-8371 and file an IND for CTX-10726.

Bears Say

Event Accrual RateManagement confirmed the trial is proceeding smoothly without any operational issues that could explain the slow event accrual rate.

Valuation ConcernsThe valuation is predicated on a ~3x EV/5-year forward sales estimate, which is a premium to the small cap peer group trading at ~1x.

Compass Therapeutics News

Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Drive Buy Rating

Leerink Partners analyst Andrew Berens has maintained their bullish stance on CMPX stock, giving a Buy rating yesterday....

29d ago

CMPX

Promising Outlook for Compass Therapeutics: Buy Rating Backed by Tovecimig’s Potential and Strategic Positioning

Sean McCutcheon, an analyst from Raymond James, has initiated a new Buy rating on Compass Therapeutics (CMPX). Sean...

1M ago

CMPX

Compass Therapeutics resumed with an Outperform at Raymond James

Raymond James analyst Sean McCutcheon resumed coverage of Compass Therapeutics (CMPX) with an Outperform rating and $9 price...

1M ago

CMPX

Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer

Compass Therapeutics, Inc. (($CMPX)) announced an update on their ongoing clinical study. Compass Therapeutics, Inc. (CMPX) recently completed...

1M ago

CMPX

Compass Therapeutics Confirms Directors at Annual Meeting

Compass Therapeutics ( ($CMPX) ) has issued an update. On June 11, 2025, Compass Therapeutics, Inc. held its...

2M ago

CMPX

Compass Therapeutics management to meet virtually with Piper Sandler

Virtual Meeting to be held on June 13 hosted by Piper Sandler. Published first on TheFly – the...

2M ago

CMPX

Compass Therapeutics: Positive Drug Data and Strategic Expansion Justify Buy Rating

Compass Therapeutics (CMPX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

3M ago

CMPX

Compass Therapeutics price target lowered to $10 from $12 at Guggenheim

Guggenheim lowered the firm’s price target on Compass Therapeutics (CMPX) to $10 from $12 and keeps a Buy...

3M ago

CMPX

Compass Therapeutics Reports Q1 2025 Financial Results

Compass Therapeutics, Inc. ( ($CMPX) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

CMPX

Compass Therapeutics reports Q1 EPS (12c), consensus (11c)

“We’re proud of the progress we’ve made this quarter, especially the achievement of the primary endpoint in our...

3M ago

CMPX

Compass Therapeutics has anticipated cash runway into 2027

As of March 31, 2025, cash and marketable securities were $113 million as compared to $127 million as...

3M ago

CMPX

Compass Therapeutics presents data on efficacy of CTX-471

Compass Therapeutics (CMPX) announced its poster presentation entitled “Enhanced Efficacy of CTX-471, A CD137 Agonist Antibody, In Models...

3M ago

CMPX

Compass Therapeutics’ Tovecimig Shows Promise in BTC Treatment, Supporting Buy Rating

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report) today and...

3M ago

CMPX

Compass Therapeutics announces first patient dosed in IST evaluating tovecimig

Compass Therapeutics (CMPX) announced the first patient has been dosed in an Investigator Sponsored Trial, IST, to evaluate...

3M ago

CMPX

CMPX FAQ

What was Compass Therapeutics’s price range in the past 12 months?

Compass Therapeutics lowest stock price was $0.87 and its highest was $4.08 in the past 12 months.

What is Compass Therapeutics’s market cap?

Compass Therapeutics’s market cap is $438.36M.

When is Compass Therapeutics’s upcoming earnings report date?

Compass Therapeutics’s upcoming earnings report date is Jul 30, 2025 which is yesterday.

How were Compass Therapeutics’s earnings last quarter?

Compass Therapeutics released its earnings results on May 08, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.01.

Is Compass Therapeutics overvalued?

According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Compass Therapeutics pay dividends?

Compass Therapeutics does not currently pay dividends.

What is Compass Therapeutics’s EPS estimate?

Compass Therapeutics’s EPS estimate is -0.12.

How many shares outstanding does Compass Therapeutics have?

Compass Therapeutics has 138,282,500 shares outstanding.

What happened to Compass Therapeutics’s price movement after its last earnings report?

Compass Therapeutics reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -3.785%.

Which hedge fund is a major shareholder of Compass Therapeutics?

Currently, no hedge funds are holding shares in CMPX

Compass Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-41.31%

Trailing 12-Months

Asset Growth

-18.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Compass Therapeutics

Compass Therapeutics (CMPX) is a clinical-stage biotechnology company focused on developing and commercializing next-generation antibody therapeutics. The company operates in the biopharmaceutical sector, concentrating on innovative treatments that target complex diseases such as cancer and autoimmune disorders. Compass Therapeutics leverages its proprietary StitchMabsTM technology, which enables the development of bispecific and multispecific antibody therapeutics aimed at enhancing immune system response and improving patient outcomes.

Compass Therapeutics (CMPX) Earnings & Revenues

CMPX Earnings Data >

CMPX Stock 12 Month Forecast

Average Price Target

$13.20

▲(332.79%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","25":"$25","6.25":"$6.25","12.5":"$12.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.25,12.5,18.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.58,4.227692307692308,5.875384615384616,7.523076923076923,9.170769230769231,10.81846153846154,12.466153846153846,14.113846153846154,15.761538461538462,17.40923076923077,19.056923076923077,20.704615384615387,22.35230769230769,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.58,3.396923076923077,4.213846153846154,5.030769230769231,5.8476923076923075,6.664615384615384,7.481538461538461,8.298461538461538,9.115384615384615,9.932307692307692,10.749230769230769,11.566153846153846,12.383076923076922,{"y":13.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.58,3.073846153846154,3.5676923076923077,4.061538461538461,4.555384615384615,5.049230769230769,5.543076923076923,6.036923076923077,6.530769230769231,7.024615384615385,7.518461538461539,8.012307692307692,8.506153846153847,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.84,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >